NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
CC E-045-2016-0-US-01 Recurrent Neural Feedback Model For Automated Image Annotation US 62/302,084 Abandoned
CC E-046-2016-0-US-01 Category Discovery And Image Auto-Annotation Via Looped Deep Pseudo-Task Optimization US 62/302,096 Abandoned
NIAID E-242-2014-0-US-03 Anti-Malarial Compositions US DIV 15/056,458 1016-08-02 Issued PDF
NCATS E-072-2015-0-US-15 DEVICE AND METHODS OF USING DEVICE FOR DETECTION OF HYPERAMMONEMIA US National Stage 14/915,602 9952199 Issued PDF
NHLBI E-249-2006-3-US-01 Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure and Coronary Artery and Myocardial Protection Device US CIP 15/056,599 9943409 Issued PDF
NCATS E-072-2015-0-CO-09 DEVICE AND METHODS OF USING DEVICE FOR DETECTION OF HYPERAMMONEMA CO National Stage 16051864 Pending
NCATS E-072-2015-0-KR-13 DEVICE AND METHODS OF USING DEVICE FOR DETECTION OF HYPERAMMONEMA KR National Stage 1020167008373 Pending
NIAID E-106-2016-0-US-01 PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE US 62/300,822 Abandoned
NIAID E-219-2016-0-US-04 Serum Antibody Assay For Determining Protection From Malaria, And Pre-Erythrocytic Subunit Vaccines US National Stage 14/914,869 Abandoned
NIAID E-239-2014-0-PCT-02 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE PCT PCT PCT/US2016/019395 Expired
NIAID E-239-2014-0-EP-03 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE EP National Stage 16711059.2 Abandoned
NIAID E-052-2017-1-EP-01 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection EP ORD 16305211.1 Pending
NCI E-105-2016-0-US-01 Methods of Producing T Cell Populations Using Hyperkalemic Cell Culture Medium US 62/299,095 Abandoned
NCATS E-072-2015-0-IL-11 DEVICE AND METHODS OF USING DEVICE FOR DETECTION OF HYPERAMMONEMA IL National Stage 244274 Pending
NCI E-116-2001-0-GR-70 Formulation of Boronic Acid Compounds GR EP 16157001.5 Expired
NCI E-116-2001-0-IT-72 Formulation of Boronic Acid Compounds IT EP 16157001.5 Expired
NCI E-116-2001-0-IE-71 Formulation of Boronic Acid Compounds IE EP 16157001.5 Expired
NCI E-116-2001-0-EP-59 Formulation of Boronic Acid Compounds EP DIV 16157001.5 Expired
NCI E-116-2001-0-SE-78 Formulation of Boronic Acid Compounds SE EP 16157001.5 Expired
NCI E-116-2001-0-PT-77 Formulation of Boronic Acid Compounds PT EP 16157001.5 Expired
NCI E-116-2001-0-ES-66 Formulation of Boronic Acid Compounds ES EP 16157001.5 Expired
NCI E-116-2001-0-BE-61 Formulation of Boronic Acid Compounds BE EP 16157001.5 Expired
NCI E-116-2001-0-AT-60 Formulation of Boronic Acid Compounds AT EP 16157001.5 Expired
NCI E-116-2001-0-TR-79 Formulation of Boronic Acid Compounds TR EP 16157001.5 Expired
NCI E-116-2001-0-GB-69 Formulation of Boronic Acid Compounds GB EP 16157001.5 Expired
NCI E-116-2001-0-CH-62 Formulation of Boronic Acid Compounds CH EP 16157001.5 Expired
NCI E-116-2001-0-LU-74 Formulation of Boronic Acid Compounds LU EP 16157001.5 Expired
NCI E-116-2001-0-NL-76 Formulation of Boronic Acid Compounds NL EP 16157001.5 Expired
NCI E-116-2001-0-MC-75 Formulation of Boronic Acid Compounds MC EP 16157001.5 Expired
NCI E-116-2001-0-LI-73 Formulation of Boronic Acid Compounds LI EP 16157001.5 Expired
NCI E-116-2001-0-FI-67 Formulation of Boronic Acid Compounds FI EP 16157001.5 Expired
NCI E-116-2001-0-FR-68 Formulation of Boronic Acid Compounds FR EP 16157001.5 Expired
NCI E-116-2001-0-DE-64 Formulation of Boronic Acid Compounds DE EP 16157001.5 Expired
NCI E-116-2001-0-CY-63 Formulation of Boronic Acid Compounds CY EP 16157001.5 Expired
NCI E-116-2001-0-DK-65 Formulation of Boronic Acid Compounds DK EP 16157001.5 Expired
NHGRI E-092-2014-1-PCT-02 Sialylation-Increasing Therapies For Diseases Associated With Oxidative Stress PCT PCT PCT/US2016/019084 Expired
NHGRI E-007-1999-2-US-10 Cellular Arrays and Methods of Detecting and Using Genetic Disorder Markers US CON 15/051,147 Expired
NHGRI E-092-2014-1-EP-04 Sialylation-Increasing Therapies For Diseases Associated With Oxidative Stress EP National Stage 16714599.4 Abandoned
NHGRI E-092-2014-1-CA-03 Sialylation-Increasing Therapies For Diseases Associated With Oxidative Stress CA National Stage 2979640 Abandoned
NINDS E-143-2002-1-JP-47 Method For the Treatment of Multiple Sclerosis JP DIV 2016-030540 Abandoned
NCI E-291-2012-0-HK-12 M971 Chimeric Antigen Receptors HK National Stage 16101891.0 Issued
NCATS E-088-2016-1-US-01 INHIBITORS OF HUMAN 12/15-LIPOXYGENASE US CIP 15/048,330 10287279 Issued PDF
NCI E-082-2015-0-US-01 SNP-Based Assay To Predict Breast Cancer Survival US 62/297,557 Abandoned
NIAID E-021-2019-0-EP-04 CONFORMATIONALLY-STABILIZED RSV PREFUSION F PROTEIN EP National Stage 14750115.9 Issued
NIDDK E-102-2011-0-US-06 COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES US DIV 15/046,630 9526739 Issued PDF
NIAID E-021-2019-0-IE-16 CONFORMATIONALLY-STABILIZED RSV PREFUSION F PROTEIN IE EP 14750115.9 Pending
NIAID E-021-2019-0-IT-17 CONFORMATIONALLY-STABILIZED RSV PREFUSION F PROTEIN IT EP 14750115.9 Pending
NIAID E-021-2019-0-NL-18 CONFORMATIONALLY-STABILIZED RSV PREFUSION F PROTEIN NL EP 14750115.9 Pending
NIAID E-021-2019-0-GB-15 CONFORMATIONALLY-STABILIZED RSV PREFUSION F PROTEIN GB EP 14750115.9 Pending
NIAID E-021-2019-0-CH-11 CONFORMATIONALLY-STABILIZED RSV PREFUSION F PROTEIN CH EP 14750115.9 Pending